Price basis
Starting amount; duration unconfirmed
Regulatory status
Compounded; not FDA-approved

Use the current offer, then verify its denominator

The live IVY RX sermorelin injection page currently starts at $179 and says use varies. Older fetched material contained a different plan table, so we do not use that table as a current monthly quote. The live starting offer is the catalog value, with its unresolved supply period clearly identified.

A meaningful estimate needs the vial quantity, concentration, intended supply duration and payment schedule attached to the actual prescription. Without those details, multiplying the entry amount by twelve would produce a hypothetical budget. This article does not infer a dose or a number of injections from an advertising price.

Follow the prescription pathway

IVY RX describes an online questionnaire and clinician review, followed by dispensing if the person is approved. The page advertises free, temperature-controlled delivery and same-day review. Those statements concern different stages; review timing is not a guarantee of prescription approval or arrival of the medication on a particular day.

Before enrolling, identify the clinician and the dispensing pharmacy, confirm state availability and ask how later clinical questions are handled. We have not tested that process as a patient. Customer testimonials and a general company rating are not evidence of this specific preparation's effectiveness, nor are they measurements of the follow-up care a reader will receive.

Clarify laboratory and monitoring expectations

The opening page says labwork is not required, while later eligibility language refers to laboratory findings. Rather than turning either statement into personal medical advice, ask what assessment the clinician needs, why any tests are proposed and whether they create additional charges. A fast purchase pathway should not prevent a careful discussion of the underlying concern.

Adult growth-hormone deficiency has a defined clinical evaluation, as described by the Endocrine Society. That source should not be misread as support for prescribing sermorelin to everyone with age-related symptoms. The relevant questions are what condition is being considered, what evidence supports the treatment and how benefit or adverse effects would be reviewed.

Understand what is and is not approved

The product is presented as a compounded prescription preparation. IVY RX's FAQ acknowledges that it is not an FDA-approved drug product. Historical Geref approval does not transfer to a new compounded vial, a different formulation or adult wellness claims. FDA also distinguishes compounded preparations from approved generic drugs.

The provider describes several quality tests, but this publication has not independently inspected a report for a dispensed batch. Such documentation would address preparation quality, not prove the advertised changes in energy, recovery or body composition. Ask the prescriber to explain the clinical evidence separately from the pharmacy's manufacturing statements.

Establish the exit terms before the first order

The published policy does not accept returns and asks customers with concerns to contact support. That is not a complete explanation of when a future order can be canceled, whether an unprocessed order can be refunded or how an early clinical stop affects a prepaid plan. Get the applicable answers in writing.

The offering is useful to include because it names the injection route and provides a current starting amount. Its main limitation is the information still needed to turn that amount into a comparable care budget. Review those gaps alongside the clinical rationale, and retain the separate provider profile for service-level questions.

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. IVY RX: rendered sermorelin injection offer Provider
  2. IVY RX: refund and return policy Provider
  3. FDA: Understanding the Risks of Compounded Drugs Regulatory
  4. FDA determination on discontinued Geref products, March 4, 2013 Regulatory
  5. Endocrine Society: Evaluation and Treatment of Adult Growth Hormone Deficiency Clinical